Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Spinocerebellar ataxia type 4 (SCA4) is a very rare progressive and untreatable subtype of type I autosomal dominant cerebellar ataxia (ADCA type I) characterized by ataxia with sensory neuropathy.
Data assembled from 8 of 12 sources · Last updated Sep 18, 2026, 7:15 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Features include: Hyporeflexia, Babinski sign, Shrinkage of the cerebellum (cerebellar atrophy), and Dysarthria and 6 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 5 | Hyporeflexia, Babinski sign, Dysarthria |
Muscles | 1 | Shrinkage of the cerebellum (cerebellar atrophy) |
Arms and legs | 1 | Limb dysmetria |
Spinocerebellar ataxia type 4 (SCA4) is a progressive neurologic disease characterized over time by cerebellar/ brain stem involvement, sensory neuropathy, upper and lower motor neuron involvement, and autonomic dysfunction as well as less common signs and symptoms including weight loss. To date, more than 200 affected individuals have been identified in families with SCA4. For many reports only historical information is available; however, several publications have provided information on modern genetic studies and more detailed clinical information on individuals and kindreds described previously [, , , , ]. Recently, clinical assessments on more than 50 individuals have been reported [, , , , ].
Source: GeneReviews — "Spinocerebellar Ataxia Type 4"
ZFHX3 function has not been fully characterized.
Spinocerebellar ataxia type 4 is associated with mutations in the ZFHX3 gene on chromosome 16.
Genotype-phenotype correlations to date are preliminary as data are only available on 35 individuals with SCA4 whose repeat sizes have been studied by long-read sequencing [, , , , ] and 26 individuals studied with PCR fragment analysis . Age of onset correlates inversely with the GGC repeat size; however, the correlation is not perfect, suggesting that unidentified additional genetic or non-genetic factors may also affect the age of onset.
The longest pathogenic repeat, 74 GGC repeats, was observed in an individual whose balance disturbances started at age 15 years.
The shortest pathogenic repeat, 44 GGC repeats, was observed in an individual whose disease onset was at age 60 years.
Source: GeneReviews — "Spinocerebellar Ataxia Type 4"
To date, ZFHX3 repeats with 42 or more GGC triplets have only been found in individuals with SCA4, whereas more than 46,000 alleles from individuals without SCA4 had at the most 30 GGC triplets, suggesting high, possibly complete, penetrance of expanded repeats with 42 triplets or more. Penetrance is age dependent, with onset between ages 12 and 65 years in all individuals with SCA4 reported to date.
Source: GeneReviews — "Spinocerebellar Ataxia Type 4"
No consensus diagnostic criteria for spinocerebellar ataxia type 4 (SCA4) have been published.
Spinocerebellar ataxia type 4 (SCA4) should be considered in probands with the following clinical and imaging findings and family history [, , , , , ].
Age of onset ranges from 12 to 65 years. About 10% of individuals have early onset (i.e., before age 25 years).
Progressive cerebellar/ brain stem involvement
Source: GeneReviews — "Spinocerebellar Ataxia Type 4"
Although spinocerebellar ataxia type 4 (SCA4) is characterized by sensory impairment, slow saccades, and autonomic dysfunction, it is difficult and often impossible to distinguish SCA4 from other hereditary ataxias based on clinical examination alone. Molecular genetic testing is highly recommended to make an accurate diagnosis. (See Hereditary Ataxia Overview for a review of the differential diagnosis of hereditary ataxia and causes of hereditary ataxia.) lists a selection of known genetic disorders with ataxia, neuropathy, and/or slow saccades that may form the most common differential diagnoses of SCA4 in clinical practice. (This list is not comprehensive, as many additional genetic disorders may be mistaken for SCA4.) Table 2. Genetic Disorders with Ataxia, Sensory Neuropathy, and/or Slow or Hypermetric Ocular Saccades in the Differential Diagnosis of Spinocerebellar Ataxia Type 4
Gene(s) | Disorder | MOI | Features of Disorder |
|---|---|---|---|
SCA1 |
Genetic testing for ZFHX3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for spinocerebellar ataxia type 4 has been reported in the published literature.
No approved treatments are currently available for spinocerebellar ataxia type 4. The disease remains an area of unmet medical need.
No clinical practice guidelines for spinocerebellar ataxia type 4 (SCA4) have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease and needs in an individual diagnosed with SCA4, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 3.
Spinocerebellar Ataxia Type 4: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Neurologic assessment for cerebellar motor dysfunction (gait postural ataxia, dysmetria, dysdiadochokinesis, tremor, dysarthria, nystagmus) | Use clinical neurologic eval standardized scale to establish baseline for ataxia, such as SARA.1
Assessment for non-cerebellar signs (vibration sense, other sensory modalities, Romberg test/ sensory ataxia, weakness, amyotrophy, reflexes, dysphagia, movement disorders, involuntary facial movements) | • Use clinical neurologic eval
Consider nerve conduction studies to establish presence severity of sensory neuropathy.
Assessment for symptoms of autonomic dysfunction:
Dizziness, lightheadedness, fainting, falls when standing up
Urinary dysfunction
Sexual dysfunction
Constipation, diarrhea, fecal incontinence
Flushing, abnormal sweating
| • Use standardized measurement of orthostatic blood pressure.2
Source: GeneReviews — "Spinocerebellar Ataxia Type 4"
Persons with SCA4 can be advised to avoid the following:
Drinking alcohol, which can further reduce cerebellar function, especially if excessive
Sedating drugs, which may reduce cerebellar function
Any other agents that may impair balance or lower blood pressure
Large carbohydrate-rich meals, as they may cause postprandial hypotension and exacerbate orthostatic decreases in blood pressure
Dehydration, especially in high ambient temperatures, as it may exacerbate hypotension
The benefit of the use of diuretics or antihypertensive agents needs to be balanced against the risk of increasing orthostatic hypotension .
Source: GeneReviews — "Spinocerebellar Ataxia Type 4"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Spinocerebellar Ataxia Type 4"
1 trial found
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 5. Spinocerebellar Ataxia Type 4: Recommended Surveillance
System/Concern | Evaluation | Frequency |
|---|---|---|
Autonomic dysfunction | Repeat clinical assessment of manifestations of autonomic dysfunction . | At least annually; more often if new symptoms occur |
Dysarthria | Eval re need for speech therapy or methods of augmentative alternative communication | Per symptom progression Dysphagia/ Weight loss |
Mood/Cognition/Behavior | Assess for mood mild cognitive or behavioral changes. | At least annually or as needed |
Family/Community | Assess family need for social work support, care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning). | At each visit OT = occupational therapy/therapist; PT = physical therapy/therapist; SARA = Scale for the Assessment and Rating of Ataxia 1. |
Source: GeneReviews — "Spinocerebellar Ataxia Type 4"
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
153 publications have been identified in PubMed for spinocerebellar ataxia type 4. Research spans Basic Science / Preclinical (33%), Review / Meta-Analysis (22%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 51 | 33% |
Research summaries | 33 | 22% |
Disease patterns and progression | 27 | 18% |
Testing and diagnosis research | 14 | 9% |
Patient case studies | 11 | 7% |
Clinical study results | 9 | 6% |
New treatment approaches | 5 | 3% |
Other research | 3 | 2% |
Xu M (2026). [PMID: 41421454](https://pubmed.ncbi.nlm.nih.gov/41421454/). *Neurobiol Dis*. [Basic Science / Preclinical]
Pankaj P (2026). [PMID: 41326055](https://pubmed.ncbi.nlm.nih.gov/41326055/). *Magn Reson Chem*. [Basic Science / Preclinical]
Henriques C (2026). [PMID: 41077785](https://pubmed.ncbi.nlm.nih.gov/41077785/). *Mol Ther*. [Gene Therapy / Novel Therapeutics]
Mancini M (2026). [PMID: 41456196](https://pubmed.ncbi.nlm.nih.gov/41456196/). *Neurorehabil Neural Repair*. [Clinical Trial Publication]
Yellaturi SR (2026). [PMID: 42220968](https://pubmed.ncbi.nlm.nih.gov/42220968/). *Tremor Other Hyperkinet Mov (N Y)*. [Review / Meta-Analysis]
Erdmann H (2026). [PMID: 40898875](https://pubmed.ncbi.nlm.nih.gov/40898875/). *Brain*. [Epidemiology / Natural History]
Petit E (2026). [PMID: 41150672](https://pubmed.ncbi.nlm.nih.gov/41150672/). *Brain*. [Diagnostic / Biomarker]
Romano LE (2026). [PMID: 41771688](https://pubmed.ncbi.nlm.nih.gov/41771688/). *Life Sci Alliance*. [Basic Science / Preclinical]
Kerkhof LMC (2026). [PMID: 41620186](https://pubmed.ncbi.nlm.nih.gov/41620186/). *Neurobiol Dis*. [Basic Science / Preclinical]
Peppel L (2026). [PMID: 40350965](https://pubmed.ncbi.nlm.nih.gov/40350965/). *J Neuropsychiatry Clin Neurosci*. [Basic Science / Preclinical]
Progressive cerebellar ataxia; Slow or hypermetric ocular saccades; Sensory neuropathy |
Spasticity; More prominent/earlier bulbar dysfunction (speech, swallowing); Cognitive dysfunction; Usually mixed sensorimotor neuropathy ATXN2 |
SCA2 | AD | Progressive cerebellar ataxia; Slow or hypermetric ocular saccades; Predominantly sensory neuropathy in many persons | Parkinsonism, tremor; muscle tone; Not all persons have neuropathy ATXN3 |
SCA3 | AD | Progressive cerebellar ataxia; Slow or hypermetric ocular saccades; Predominantly sensory neuro(no)pathy in some individuals; Amyotrophy | Parkinsonism; Action-induced facial lingual fasciculations; Bulging eyes; May have motor or sensorimotor neuro(no)pathy RFC1 |
RFC1 CANVAS/ spectrum disorder | AR | Progressive cerebellar ataxia; Sensory neuropathy; Autonomic dysfunction | Abnormal or absent vestibulo-ocular reflex; Chronic cough; Prominent neuropathic pain FXN |
Friedreich ataxia | AR | Progressive cerebellar ataxia; vibration sense; Muscular weakness; Bladder dysfunction; Neuropathy | Usually sensorimotor neuropathy; Scoliosis; Hearing vision loss; Cardiomyopathy; Usually earlier onset TDP1 |
SCA w/axonal neuropathy type 1 | AR | Progressive cerebellar ataxia; Distal sensory impairment | More commonly early onset in late childhood to adolescence; Develop motor neuropathy peripheral weakness; Nystagmus; No saccadic slowing described TTPA |
Ataxia w/vitamin E deficiency | AR | Progressive ataxia; Upper lower motor neuron signs; Purely sensory neuropathy in subset of persons | Manifests more commonly in childhood; Retinopathy; Very low plasma vitamin E concentration; Neuropathy may be purely motor or sensorimotor Based on , , , AD = autosomal dominant; AR = autosomal recessive; CANVAS = ce... |
Source: GeneReviews — "Spinocerebellar Ataxia Type 4"